Group Cognitive Therapy Reduces Negative Symptoms in Early Psychosis

Targeting the Cognitive Drivers of Negative Symptoms in Psychosis

Schizophrenia spectrum disorders impose a substantial global burden, frequently leading to years lived with disability due to persistent functional impairments [1]. While pharmacological and standard psychological interventions effectively manage positive symptoms like hallucinations, negative symptoms such as avolition and social withdrawal remain largely refractory to treatment [2, 3]. These deficits are closely linked to poor social functioning and long-term morbidity, necessitating the development of specialized behavioral strategies [4, 5]. Recent research has increasingly focused on repetitive negative thinking as a potential maintenance factor for these debilitating symptoms [6]. A recent randomized clinical trial evaluates whether a targeted cognitive intervention can bridge this therapeutic gap by addressing the underlying patterns of rumination in early psychosis, offering clinicians a potential new tool for managing treatment-resistant deficit symptoms.

Trial Design and Intervention Feasibility

The researchers conducted a pilot randomized clinical trial to evaluate the feasibility and efficacy of adding group rumination-focused cognitive behavioral therapy (RFCBT) to standard early outpatient care, known as OPUS. RFCBT is a specialized psychological intervention that targets the mechanical process of dwelling on distress rather than simply challenging the content of negative thoughts. The study population consisted of young adults with schizophrenia spectrum disorders who were already receiving OPUS care. These participants were randomized in a 1:1 ratio to receive either 13 weeks of group RFCBT plus OPUS or treatment-as-usual, which consisted of OPUS care alone. To ensure a rigorous evaluation, the authors conducted clinical assessments at baseline and immediately following the post-treatment period, utilizing Welch t-tests (a statistical method robust to unequal variances) to compare between-group differences in change scores. A total of 59 participants were initially included, but one withdrew consent, leaving 58 participants for the intention-to-treat analysis (a method that includes all randomized patients regardless of protocol adherence to reflect real-world clinical conditions). This cohort was divided into an RFCBT group (n=28) and a treatment-as-usual group (n=30). The researchers defined feasibility as at least 80 percent of the participants completing six or more therapy sessions. The intervention met this predefined threshold, as 82.14 percent of participants in the RFCBT group completed six or more sessions. This high rate of engagement among young adults in the early stages of psychosis suggests that this group-based cognitive approach is a viable addition to standard outpatient protocols, providing a foundation for larger clinical trials.

Significant Reductions in Negative Symptoms and Rumination

The primary objective of the trial was to determine if targeting repetitive negative thinking could alleviate the persistent negative symptoms that typically resist standard antipsychotic therapy. The researchers utilized the Brief Negative Symptom Scale (BNSS), a validated clinical tool measuring domains such as anhedonia, asociality, and blunted affect, as the primary outcome measure. Compared with the treatment-as-usual group, participants receiving group RFCBT demonstrated a greater improvement in BNSS scores, with a between-group difference of -5.90 (p=0.05). This reduction represents a moderate-to-large effect size (d=0.72), indicating a clinically meaningful benefit for patients struggling with the deficit symptoms of schizophrenia spectrum disorders. For practicing physicians, this suggests that addressing cognitive habits directly could help patients regain motivation and emotional resonance. The study also focused on secondary outcomes to validate the hypothesis that repetitive negative thinking drives these negative symptoms. To measure these cognitive patterns, the authors employed the Perseverative Thinking Questionnaire (PTQ), which assesses the intrusive and difficult-to-control nature of negative thoughts, and the Ruminative Responses Scale (RRS), which tracks how individuals respond to depressed moods. Both measures showed significant improvement in the RFCBT group relative to the control group. Specifically, scores on the PTQ improved by a difference of -8.35 (p=0.016; d=0.89), while the RRS showed a reduction of -9.62 (p=0.001; d=1.15). These large effect sizes demonstrate that the therapy effectively reduced the frequency and intensity of rumination. Ultimately, adding group RFCBT to standard outpatient care yielded large reductions in both negative symptoms and repetitive negative thinking relative to treatment-as-usual, highlighting a specific behavioral pathway to improve patient outcomes.

Stability of Secondary Clinical Measures

While the intervention demonstrated efficacy in reducing negative symptoms and rumination, the researchers observed that other clinical domains remained stable across both groups. Secondary outcomes included the Scale for the Assessment of Positive Symptoms (SAPS), which measures hallucinations and delusions, and the Calgary Depression Scale for Schizophrenia (CDSS), a tool specifically designed to differentiate depressive symptoms from the negative symptoms of schizophrenia. The study also evaluated cognitive and functional domains using the Behavior Rating Inventory of Executive Function (BRIEF), which assesses self-regulation and metacognition, and the Social Functioning Scale (SFS), which tracks engagement in daily living and vocational activities. No significant between-group differences were observed for SAPS, CDSS, BRIEF, or SFS, indicating that the 13-week course of therapy did not exert a broad impact on these specific clinical areas during the study period. For the practicing clinician, these null findings clarify the therapeutic profile of rumination-focused cognitive behavioral therapy. The results suggest that the intervention functions as a targeted treatment for negative symptoms and repetitive thinking rather than a generalized intervention for all facets of psychosis. Because no significant between-group differences were observed for positive symptoms or depressive symptoms, clinicians should view this therapy as a specialized adjunct to standard care, which typically manages hallucinations and mood more effectively than it does the deficit symptoms of the disorder. Furthermore, the lack of immediate change in executive and social functioning suggests that improvements in these complex domains may require more time to manifest or may necessitate additional vocational rehabilitation. Despite the lack of change in secondary measures, the feasibility of the intervention remains a key finding for outpatient settings. With 82.14 percent of participants in the intervention group completing six or more sessions, the protocol appears well tolerated by young adults in the early stages of psychosis. This group intervention provides a practical pathway for treating negative symptoms, which are often refractory to antipsychotic medications. The large reductions in negative symptoms and repetitive negative thinking support the progression to a fully powered trial to confirm these findings and further define the role of rumination-focused strategies in psychiatric practice.

References

1. Vos T, Abajobir AA, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017. doi:10.1016/s0140-6736(17)32154-2

2. Karageorgiou V, Michopoulos I, Tsigkaropoulou E. Comparative Effectiveness of Cognitive Behavioral Therapies in Schizophrenia and Schizoaffective Disorder: A Systematic Review and Meta-Regression Analysis. Journal of Clinical Medicine. 2025. doi:10.3390/jcm14155521

3. Lincoln TM, Ziegler M, Mehl S, et al. Moving from efficacy to effectiveness in cognitive behavioral therapy for psychosis: a randomized clinical practice trial.. Journal of consulting and clinical psychology. 2012. doi:10.1037/a0028665

4. Isaac C, Januel D. Neural correlates of cognitive improvements following cognitive remediation in schizophrenia: a systematic review of randomized trials. Socioaffective Neuroscience & Psychology. 2016. doi:10.3402/snp.v6.30054

5. Andrade P, Sanfins N, Azevedo J. Mend the Gap: Online User-Led Adjuvant Treatment for Psychosis: A Systematic Review on Recent Findings.. International journal of environmental research and public health. 2025. doi:10.3390/ijerph22071024

6. Arnfred B, Lund CN, Ysbæk-Nielsen AT, et al. Rumination-Focused Cognitive Behavioral Therapy for Negative Symptoms in Early Psychosis: Results of a Pilot Randomized Clinical Trial.. Psychotherapy and psychosomatics. 2026. doi:10.1159/000551732